Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Philip Morris International Inc. (PM) vs BIO-TECHNE Corp (TECH) Price & Performance

Philip Morris International Inc.Trade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Philip Morris International Inc. vs BIO-TECHNE Corp — how do they compare? Philip Morris International Inc. trades at $194.3 (market cap $293.07B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: Philip Morris International Inc. is far larger — about 26.3× BIO-TECHNE Corp's market cap, and Philip Morris International Inc. pays the higher dividend (3.13%). Which is the better fit depends on your goals.

PMTECH
Market Cap
$293.07B$11.16B
Sector
Consumer StaplesHealth
52-Week High
$192.98$72.12
52-Week Low
$144.33$43.31
Enterprise Value
$339.57B$11.24B
Dividend Yield
3.13%0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Philip Morris International Inc.

Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with strong analyst support (17 buy ratings) and a $194 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal robust profitability with 26.74% net margins and consistent revenue growth to $40.65B in 2025. Recent news includes a profit forecast revision due to a $500M impairment charge and CFO succession planning.

PM offers stable dividend income and brand strength but faces headwinds from cost pressures and illicit market growth. The stock trades at a premium valuation (P/E 27.13) with elevated debt levels, requiring monitoring of pricing power and regulatory developments. Near-term catalysts include Q2 earnings and execution of the smoke-free transition strategy.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.

The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH